Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFBS4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,844
Award facts
- Contract value 100% obligated
- $11,844.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $11,844.15 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL syringes. The contract, awarded on December 23, 2025, with an ultimate completion date of January 15, 2026, carries no set-aside designation, indicating the award was made through full and open competition. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036.
The Pharmaceutical Prime Vendor Global Program Generation V represents part of the broader $30.3 billion federal pharmaceutical supply strategy designed to ensure consistent availability of medications and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors authorized to supply a comprehensive range of pharmaceuticals, including branded and generic prescription drugs, biologics, vaccines, and specialty medical products. The company's established performance on numerous prior delivery orders demonstrates its capability to meet the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations. This specific delivery order for Xolair, an immunosuppressant biologic agent, supports ongoing military medical supply needs under firm fixed-price terms.
Quick answers
Who was awarded contract SPE2DR26FFBS4?
SPE2DR26FFBS4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FFBS4 worth?
The government has obligated $11,844 on SPE2DR26FFBS4.
Is contract SPE2DR26FFBS4 an order under another contract?
Yes. SPE2DR26FFBS4 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBS4 competed?
The extent of competition for SPE2DR26FFBS4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award